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The Janus-faced roles of macrophages in cancer imply both tumor-suppressive and -stimulating actions of these innate
immune cells. Whereas the balance is toward tumor promotion in most epithelial cancers, we have recently shown that
osteosarcomametastasisseemstobeinhibitedbymacrophages.Herewediscussthepossiblemechanismofthisobservation.
It is not a coincidence that the ‘Father
of Immunotherapy,’ William B. Coley,
was a bone sarcoma surgeon. The first
successful example of immunotherapy was
in 1891 when Coley’s toxins, a mixture of
toxins of streptococcal bacteria was
injected into an unresectable sarcoma.
The resulting immunological reaction led
to tumor regression,
1 similar to what has
been observed in osteosarcoma patients
suffering from post-operative infection
following resection of their primary
tumor. The few known permanent res-
ponses to Coley’s toxins in carcinoma were
in those cases of mesodermal origin.
2 Are
sarcomas and other tumors of mesodermal
origin more immunogenic than carcino-
mas? Or do immune cells have an effect
that is different between sarcomas and
carcinomas?
The tumor promoting effect of macro-
phages in carcinomas is well established.
Epithelial tumors with high numbers
of infiltrating immune cells have a poor
prognosis as compared with cases with few
infiltrating cells. This is attributed to a
number of properties of the immune cells,
especially macrophages, which have been
shown to be involved with tumor initia-
tion, invasion, migration, intravasation
and angiogenesis.
3 Especially the stimulat-
ing effect on tumor invasion and migra-
tion of in origin non-motile epithelial
cells that are the progenitors of carcinomas
can be well comprehended. However, it is
different for mesenchymal cells, which are
much less dependent on contact with
adjacent cells and thus more motile.
These cells probably do not need the
guidance that immune cells seem to give to
carcinoma cells in the circulation. Instead,
mesenchymal tumor cells might be inhi-
bited in their motility by macrophages,
which then act as impediment, instead of
promoter for invasion. This is of course
speculative, but it has been reported that
macrophage inhibitory factor, MIF, which
is produced by macrophages, inhibits
migration of mesenchymal stem cells.
4
Our recent report describing an expres-
sion profiling study in a relatively large
series of high grade, central osteosarcomas
corroborates a metastasis inhibiting role
for macrophages.
5 The ‘expression profile’
associated with non-metastatic behavior of
osteosarcoma surprisingly consisted of a
majority of genes associated with macro-
phage function, such as antigen processing
and presentation or pattern recognition, as
well as specific monocyte and macrophage
markers such as CD14 and MSR1. Also
genes related to general immunological
expression were found to be upregulated,
including several hematopoietic markers
and cytokines. Expression of the macro-
phage-associated genes was confined to
primary tumor tissue and not detected in
a panel of 19 osteosarcoma cell line RNA
samples, indicating that infiltrating
immune cells were responsible for this
expression profile. Furthermore the results
were confirmed at the protein level by
immuno histochemical staining on a larger
patient cohort.
Osteosarcoma is an extremely aggressive
tumor, mostly affecting adolescents.
Neoadjuvant chemotherapy and limb-
sparing salvage surgery have improved
outcome and quality of life, but the last
quarter-century no innovation and no
improved survival has been achieved and
oncologists are still left with about 40% of
patients who die as a result of non-curable
metastatic disease.
A role for macrophages to prevent or
reduce metastases of osteosarcoma is
corroborated by one of the few minor
efficacious new therapeutic agents that
were tested since the successful introduc-
tion of conventional chemotherapy for
osteosarcoma, i.e., liposomal muramyl tri-
peptide (MTP), also known as Mepact or
Mifurmatide. This proprietary drug elicits
activation of macrophages. Although the
clinical trial that included adjuvant treat-
ment with Mepact was initially denounced
because of presumed interaction with one
of the chemotherapeutic compounds
6 it
eventually appeared to give an improve-
ment from 70 to 78% survival, which was
the best achievement in improving out-
come in decades.
7 Our finding that macro-
phages are associated with less metastases
now provides a valid rationale for the
efficacy of this drug. Additional supportive
proof for the effectiveness of immune-
stimulation is the use of interferon-a as
adjuvant therapy in osteosarcoma
8 albeit
that the positive effect may involve
both immunological and direct anti-
tumor effects. The recently completed
*Correspondence to: Anne-Marie Cleton-Jansen; Email: a.m.cleton-jansen@lumc.nl
Submitted: 10/05/11; Accepted: 10/07/11
http://dx.doi.org/10.4161/onci.1.2.18345
AUTHOR'S VIEW
OncoImmunology 1:2, 255–257; March/April 2012; G 2012 Landes Bioscience
www.landesbioscience.com OncoImmunology 255© 2012 Landes Bioscience.
Do not distribute.
EURAMOS1 clinical will shed more light
on the value of this drug, since it was
included in one of the randomized arms.
9
Neither the mechanism of metastasis
suppression in osteosarcoma is clarified,
nor the contrast with epithelial tumors. It
may be sought in the different flavors of
macrophages that are distinguishable by
specific markers. M1 are tumor suppress-
ive, M2 support invasion, metastasis and
angiogenesis of tumor cells. We assessed
the nature of the tumor associated macro-
phages in osteosarcoma clinical samples
using HLA-DRa, associated with M1
macrophages and CD163, a marker to
distinguish M2. Surprisingly both types of
macrophages were present in the tumor
tissues analyzed (Fig.1). Recent percep-
tions on the good vs. bad macrophages are
more nuanced. Macrophages are con-
sidered as quite flexible cells that polarize
to a certain direction, but are not destined
to stay that way.
To complicate things even more, there
was a recent report that macrophage infiltra-
tion in another primary bone tumor, Ewing
sarcoma, predicts a poor prognosis.
10
Similar to epithelial cancers, high macro-
phage infiltration was associated with
increased microvessel density in our study,
suggesting a similar role for macrophages
in the promotion of angiogenesis in osteo-
sarcoma. However, in the case of osteo-
sarcoma, the influx of pro-angiogenic
macrophages may be similar to a “Trojan
horse.” Perhaps macrophages are attracted
by the tumor to support angiogenesis, but
following chemotherapeutic treatment, the
release of endogenous danger signals by
dying tumor cells causes the macrophages to
become polarized toward an M1, anti-
tumor phenotype. This proposed mech-
anism is supported by the fact that the
survival benefit of high macrophage infiltra-
tion in our study was partly dependent on
histological response to chemotherapy.
Coley’st o x i n sw e r ed e n o u n c e db y
another famous bone sarcoma expert, the
pathologist James Ewing who gave his name
to the second aggressive pediatric bone
tumor. Ewing was not charmed by the
medieval treatment developed by Coley, he
was afervent proponent ofradiationtherapy,
which was effective for many tumors, but
ironically not for bone sarcomas.
In conclusion, the relatively good
response of sarcomas to immune stimu-
lation and the favorable prognostic effect of
tumor associated macrophages as opposed
tocarcinomas suggests that tumor immuno-
logy is different for sarcomas. This does not
seemattributabletoaparticularmacrophage
subtype, but lies in the nature of this tumor
type.Fewclinicaltrialshavebeenconducted
on immunotherapy in sarcomas. Given our
findings that macrophages are associated
with less metastases in osteosarcoma tumor
immunotherapy specifically targeted at this
tumor type should be seriously evaluated.
Figure1. Osteosarcoma samples are infiltrated with CD14 and CD163 single and double positive macrophages. Spectral imaging was used to reduce
autofluorescence of osteosarcoma cells. In the composite image, CD14-positive cells are represented in green, CD163-positive cells are represented in
red, and CD14/CD163 double positive cells are represented in yellow. Background autofluorescence of tumor cells is represented in gray.
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